25,729 articles
Fexinidazole
Fexinidazole (HOE 239), a 5-nitroimidazole oral drug by DNDi and Sanofi, is the first all-oral 10-day treatment for both stages of gambiense and rhodesiense sleeping sickness, EMA-recommended 2018, FDA-approved 2021.
Fexofenadine
Fexofenadine (Allegra) is a second-generation, nonsedating H1 antihistamine for allergic rhinitis and chronic urticaria, approved in 1996 as the active metabolite of the withdrawn drug terfenadine (Seldane).
FG-M701
FG-M701 (ABBV-701) is a fully human anti-TL1A monoclonal antibody for inflammatory bowel disease developed by FutureGen Biopharmaceutical (明济生物) and exclusively licensed to AbbVie in June 2024 for $150 million upfront plus up to $1.56 billion in milestones; distinct from the unrelated M701 EpCAM-CD3 bispecific.
FH study
The Fetal-Hope (FH) study, NCT05958446, is an Italian multicenter observational trial testing home fetal heart rate monitoring with a handheld Doppler in anti-Ro/SSA-positive pregnant women to detect fetal atrioventricular block early.
FHLPA study
FHLPA (Lp(a) and Aortic Valve Calcification), ClinicalTrials.gov NCT02976818, a completed Laval University study led by Patrick Couture on lipoprotein(a), familial hypercholesterolemia, and aortic valve calcification; no results posted.
Fiberoptic endoscopic evaluation of swallowing
Fiberoptic endoscopic evaluation of swallowing (FEES) is a bedside procedure in which a flexible laryngoscope passed through the nose assesses swallowing and aspiration risk, first described in 1988.
Fiboflapon
Fiboflapon (GSK2190915, formerly AM803) is an investigational oral 5-lipoxygenase-activating protein (FLAP) inhibitor developed for asthma; it suppresses leukotriene B4 and cysteinyl leukotrienes, half-life 16-34 h, not approved.
Fibrinogen
Fibrinogen (coagulation factor I) is a 340-kDa plasma glycoprotein that thrombin converts to fibrin for blood clotting; also an acute-phase protein and studied cardiovascular risk marker, with concentrate therapies for congenital deficiency.
Fibrinogen i 125
Fibrinogen i 125 (^{125}I-fibrinogen) is iodine-125-labeled fibrinogen used from 1965 in the fibrinogen uptake test to detect deep vein thrombosis; accurate for calf clots but limited in the thigh and later superseded.
Fibrinolysis
Fibrinolysis, also called clot lysis or fibrin breakdown, is the plasmin-mediated degradation of fibrin blood clots, regulated by tPA, uPA, PAI-1, alpha2-antiplasmin, and TAFI, and targeted by thrombolytic and antifibrinolytic drugs such as tranexamic acid.
Fibrinolytic therapy
Fibrinolytic therapy is drug treatment that dissolves blood clots by converting plasminogen to plasmin, used in heart attack, stroke, and pulmonary embolism, with bleeding as its main risk.
Fibrinopeptide A
Fibrinopeptide A is a 16-residue peptide cleaved from fibrinogen by thrombin during blood coagulation, exposing polymerization sites for clot formation and serving as a clinical marker of thrombin activity.
Fibro-adipose vascular anomaly
Fibro-adipose vascular anomaly (FAVA), a rare ISSVA-provisionally unclassified vascular malformation first described in 2014, causes painful fibrofatty intramuscular lesions with contractures, PIK3CA mutations, and frequent misdiagnosis as venous malformation.
Fibroadenoma
Fibroadenoma, the commonest benign breast tumor, a biphasic epithelial-stromal lesion of reproductive-age women; diagnosed by triple assessment, usually observed, excised if large, growing, or discordant.
Fibroadenosis of breast
Fibroadenosis of breast, also called fibrocystic breast changes or fibrocystic breast disease, is a common benign condition with lumpy breast tissue from fibrosis, cysts, and adenosis; it does not raise breast cancer risk.
Fibroblastic disorders
Fibroblastic disorders (ICD-11 FB51) are soft-tissue conditions driven by fibroblast or myofibroblast proliferation, including palmar and plantar fibromatosis (Dupuytren, Ledderhose), knuckle pads, fibroblastic rheumatism, and retroperitoneal fibrosis.
Fibroblastic reticular cell tumour
Fibroblastic reticular cell tumour (FRCT), also called cytokeratin-positive interstitial reticulum cell tumor, is a rare malignant stromal neoplasm of lymphoid tissue (ICD-O 9759/3, ICD-11 2B31.7) affecting lymph nodes, spleen, and soft tissue, positive for cytokeratin, SMA, desmin, and CD68.
Fibroblastic rheumatism
Fibroblastic rheumatism (le rhumatisme fibroblastique), ORPHA:477650, is a rare rheumatologic disease first described in 1980, combining sudden symmetric distal polyarthritis with firm skin nodules, sclerodactyly, and fibroblastic dermal proliferation; about 30 cases reported worldwide.
Fibrochondrogenesis
Fibrochondrogenesis (ORPHA:2021, OMIM 228520/614524) is a rare, mostly neonatally lethal short-limb skeletal dysplasia from COL11A1 or COL11A2 mutations affecting type XI collagen, with flat midface, dumbbell long bones, and pinched vertebral bodies.
Fibrodysplasia ossificans progressiva
Fibrodysplasia ossificans progressiva (FOP, myositis ossificans progressiva, stone man disease) is an ultra-rare ACVR1 genetic disorder in which muscle, tendons, and ligaments progressively turn to bone, marked by congenital malformed big toes, flare-ups, and treatments palovarotene, garetosmab, and zilurgisertib.
Fibrolamellar hepatocellular carcinoma
Fibrolamellar hepatocellular carcinoma (FLC, FL-HCC) is a rare liver cancer of adolescents and young adults with healthy livers, defined by the DNAJB1::PRKACA fusion from a chromosome 19 deletion; surgery is the only curative treatment.
Fibroma
Fibroma: a benign tumor of fibrous connective tissue, also called fibrous tumor; includes plantar, non-ossifying, oral, ovarian, and skin types; malignant counterpart is fibrosarcoma.
Fibromatosis of breast
Fibromatosis of the breast, also called mammary or desmoid-type fibromatosis, is a rare, locally aggressive, non-metastasizing fibroblastic breast tumor with Wnt/beta-catenin activation, now often managed by active surveillance.
Fibromuscular dysplasia
Fibromuscular dysplasia (FMD) is an idiopathic, non-inflammatory, non-atherosclerotic arteriopathy of medium arteries, mainly renal and cervicocranial, affecting women, causing stenosis, aneurysm, dissection, and hypertension.
Fibromyalgia
Fibromyalgia, also called fibromyalgia syndrome, is a chronic disorder of widespread pain, fatigue, and sleep problems, diagnosed clinically with no biomarker. It affects about 1.5–2% of people, mostly women; exercise is first-line, drugs give only small benefits.
Fibronectin glomerulopathy
Fibronectin glomerulopathy (GFND, glomerulopathy with fibronectin deposits): rare autosomal dominant kidney disease from FN1 mutations, with fibronectin deposits in glomeruli, proteinuria, hematuria, hypertension, and end-stage renal disease in 15-20 years.
Fibropolycystic liver disease
Fibropolycystic liver disease (ductal plate malformation, fibrocystic liver disease) is a spectrum of heritable ciliopathy disorders of intrahepatic bile ducts, including congenital hepatic fibrosis, Caroli disease, biliary hamartomas, and polycystic liver disease, causing portal hypertension, cholangitis, and rarely cholangiocarcinoma.
Fibrosarcoma
Fibrosarcoma is a rare malignant tumor of fibroblastic origin arising in deep soft tissue and bone, spanning an aggressive adult form and an infantile form with excellent survival.
Fibrosis
Fibrosis, or fibrotic scarring, is the excessive buildup of scar tissue in organs such as the lung, liver, heart, and kidney after chronic injury, impairing function.
Fibrosis of spleen
Fibrosis of spleen (fibrotic spleen, ICD-11 3B81.9) is excess fibrous connective tissue causing partial or complete splenic degradation, following trauma, toxicity, inflammation, infarction, or neoplasia; confirmed by imaging and elastography.